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In this controlled before-after study based on data from the Norwegian Prescription Database, we 
examine whether starting off-label use of Low Dose Naltrexone (LDN) is followed by changes in the 
consumption of psychotropic medicines including antiepileptics. patients that collected LDn for the 
first time in 2013 (N = 11247) were included and stratified into three groups based on LDN exposure. We 
compared differences in means of cumulative number of defined daily doses (DDD) as well as changes 
in the number of users one year before and one year after starting LDn. there was a dose-response 
association between increasing LDN exposure and reductions in the number of users of antiepileptics, 
antipsychotics and antidepressants. There were significant difference-in-differences in DDDs between 
the groups with the lowest and highest LDN exposure of antipsychotics (1.4 DDD, 95% CI 0.4 to 2.3, 
p = 0.007), and in number of users of antiepileptics (3.1% points, 95% CI 1.6% to 4.6%, p < 0.001), 
antipsychotics (2.1% points, 95% CI 1.2% to 3%, p < 0.001), and antidepressants (2.8% points, 95% CI 
1.1% to 4.4%, p = 0.001). The findings show an association between the initiation of persistent LDN use 
and reduced consumption of several psychotropic medicines and antiepileptics. Beneficial effects of 
LDn in the treatment of psychiatric diseases cannot be ruled out.
Off-label use of low dose naltrexone (LDN), typically <5 mg/day, is by some patients, doctors and researchers 
believed to have therapeutic effects in several conditions such as autoimmune diseases1 and chronic pain. LDN 
could be a cheap and safe2 alternative to standard treatments, but the evidence of effect is limited. The main use 
of naltrexone within psychiatry has so far been as treatment of opioid and alcohol addiction3, but a recent report 
suggests that LDN may be helpful in other psychiatric conditions4. Some of the beneficial effects in patients with 
autoimmune diseases have been improvements in quality of life5,6 and improvements in symptoms associated 
with depression, such as sleep and mood7. In a study on major depressive disorder where the authors rand-
omized 12 patients to naltrexone 1 mg/day or placebo, there were borderline significant improvements in some 
clinical depression measures4. These results are part of the documentation in a patent application on the use of 
LDN in depression and other mental health issues8. In a randomized study on Gulf war illness (N = 37), there 
were improvements in general disability, depression and confusion in users of LDN9. There have been promising 
results in a small, randomized study in fibromyalgia, a condition where psychiatric symptoms may be prominent6.
A sudden and large increase in LDN consumption in Norway during 201310 has enabled nationwide 
quasi-experimental register studies on change in medicine use associated to initiation of LDN use. Previously we 
have demonstrated an association between starting LDN and changes in medication for inflammatory bowel dis-
ease11 and rheumatoid and seropositive arthritis12, but not in multiple sclerosis13. We have shown almost halving 
of the opioid consumption among persistent LDN users14. If there are beneficial effects of LDN in psychiatric dis-
ease, it is plausible that this will be reflected in the consumption of medicines. We aimed to test the hypothesis that 
initiation of LDN use is associated with reductions in the dispensing of psychotropic and antiepileptic medicines.
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Materials and Methods
Study design and setting. We performed a pharmacoepidemiological nationwide quasi-experimental con-
trolled before-after study using data from the Norwegian Prescription Database (NorPD). NorPD contains indi-
vidual data on all prescriptions dispensed since 2004 to the entire Norwegian population living outside hospitals. 
Details on NorPD are published previously15. Each prescription in NorPD contains a unique pseudonym for the 
personal identifier, demographic data on patient and prescriber, the specialty of the prescriber, the Anatomical 
Therapeutic Chemical classification (ATC) code and the amount of medicine in defined daily doses (DDD), date 
of dispensing, and location of the dispensing pharmacy16. It is possible to follow dispensing to individuals on both 
reimbursed and non-reimbursed prescriptions. The Norwegian Institute of Public Health hosts the database17. We 
used the following variables in this study: personal identifier, age and sex for the patient, ATC code and product 
identifying number for all prescribed medicines, date of dispensing, and dispensed volume in DDDs. For a fee, 
NorPD provided a data file according to their data access procedures.
participants. We included all Norwegian residents with at least one LDN prescription in 2013 according to 
NorPD. The date of the first dispense is the index date, and we recorded all dispensed prescriptions on psycho-
tropic and antiepileptic medicines 365 days before the index date, and from the index date +364 days.
We stratified the patients into three subgroups depending on the number of collected LDN prescriptions 
after the index date. Patients were included in the persistent user subgroup (LDN × 4+) if they collected four 
or more LDN prescriptions. The other subgroups were one-time users (LDN × 1), and intermediate LDN users 
(LDN × 2–3). The patients served as their own controls (before data) and between groups that reflect LDN expo-
sure. The LDN × 1, who likely used LDN for a short time, served as a control group compared to the LDN × 4+ 
group. The LDN × 2–3 group enabled dose-response comparisons.
The total observation time was 2 years for all participants. The first observation date was theoretically January 
1, 2012, and the last observation date was December 31, 2014.
Outcome variables. Main outcome was difference between the cumulative collected amounts of DDDs and 
number of users on antiepileptics (ATC N03A), antipsychotics (N05A), anxiolytics (N05B), hypnotics (N05C), 
antidepressants (N06A) and psychostimulants (N06B) during the 365 days preceding the index date throughout 
the 364 days succeeding the first LDN dispense. We expressed the difference for each patient by subtracting the 
number of collected DDDs within all ATC groups the year following the first LDN dispense from the number of 
DDDs in the year preceding the first LDN dispense.
As secondary outcome, we used equivalent changes in DDD and number of users of some subgroups: Tricyclic 
antidepressants (N06AA), Selective serotonin inhibitors (N06AB), other antidepressants (N06AX), benzodiaze-
pines (N05BA, N05CD, N03AE01) and z hypnotics (benzodiazepine like) (N05CF), gabapentin and pregabalin 
(N03AX12, N03AX16), lithium (N05AN) and lamotrigine (N05AX09).
Statistical methods. The number of patients in NorPD collecting a prescription on LDN in 2013 deter-
mined the study size. We used SPSS 25 and Excel 2013 for data analysis, and analyzed all data on an individual 
level. We used a pairwise two-sided t-test to determine the significance of mean changes in the sum of the DDDs 
per patient in each group for all examined medicines, and calculated 95% confidence intervals (CI) for difference 
of means. Change in the number of users was expressed as the proportion (% points) of each cohort, together with 
the 95% CI for the difference of proportion (in % points)18. Difference-in-difference of DDDs and proportion 
of users with 95% CI were calculated. The graphical representation of the cumulative difference in dispensing 
between the groups with the highest and the lowest LDN exposure (LDN × 4+–LDN × 1) before and after the 
index date is based on dispensing data.
ethics statement. The Regional Committee for Medical and Health Research Ethics of Northern Norway 
reviewed the study protocol. Due to the encrypted data, the committee concluded that disclosure was not man-
datory. The local privacy ombudsman for research at the University Hospital of Northern Norway approved the 
project. Consent from individual patients is by law not required for research based on NorPD.
Results
patients. The inclusion of patients and dispenses of outcome medicines is shown in Fig. 1. In total, 11247 
patients were included, and the observation period before and after index date constituted 69928 patient-months. 
The analyses on the examined medicines include 57951 prescriptions dispensed before and 61778 prescriptions 
dispensed after the index date.
Descriptive data. Table 1 displays baseline data of the three subgroups. There were three percentage points 
more women in the LDN × 4+ group, and the mean age was approximately one year higher in this group. There 
were no missing data on age or sex among the included. The numbers of dispenses of all outcome medicines were 
comparable in all groups.
outcome data. Mean number of dispensed DDDs before and after the first LDN prescription are summa-
rized in Table 2, and changes in the number of users are presented in Table 3. The cumulative differences between 
LDN × 1 and LDN × 4+ in dispensed DDDs of the main outcomes before and after index date are shown in 
Fig. 2. Secondary outcomes are presented in Table 4 (DDDs) and Table 5 (number of users).
For all medicines being examined, there were a 6% relative increase in DDD in both LDN × 1 and LDN × 2–3, 
and a significant difference in-difference of 11 DDD (95% CI 1.7 to 20.3, p = 0.027) between LDN x1 and 
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LDN × 4+. The number of users of any examined medicine showed a 6% reduction in LDN × 4+, a significant 
difference-in-difference compared to LDN × 1 (3.8% points, 95% CI 2.0 to 5.6, p < 0.001).
Antiepileptics. In the LDN × 1 group, there was an 11% relative increase in the use of antiepileptics (DDD), 
in contrast to a non-significant reduction in the LDN × 4+ group. In number of users, there was a significant 
difference-in-difference between these two groups (3.1% points (95% CI 1.6 to 4.6, p < 0.001)). Significant 
increase in number of users was seen in both LDN x1 (+10%) and LDN × 2–3 (+14%) compared to LDN × 4+ 
(−11%). This is mainly attributable to changes in the dispensing of gabapentin and pregabalin, which was the 
dominating antiepileptics used by the included patients (73% of observed antiepileptic DDDs).
Antipsychotics. The dispensing of antipsychotics before the index date was similar in all groups, but 
there was a significant 11% relative DDD increase in the LDN × 1 group, which represent a significant 
difference-in-difference compared to LDN × 4+ (1.4 DDD, 95% CI 0.4 to 2.3, p = 0.007). There was a 17% rel-
ative reduction in the number of antipsychotic users for the LDN × 4+ group and a 25% relative increase in 
LDN × 1, representing a significant difference-in-difference between these groups (2.1% points, 95% CI 1.2 to 
3.0, p < 0.001).
Benzodiazepines and Z hypnotics. There were increases in cumulative number of DDDs of 
benzodiazepine-like hypnotics (Z-hypnotics) in all groups, but no change in number of users. There was a signif-
icant increase in benzodiazepine DDDs for LDNx4+.
For benzodiazepines (including clonazepam), a significant increase in DDDs was seen only in LDN × 4 (+9%, 
relative). For all benzodiazepines and z-hypnotics combined, there was an increase in number of users in LDN × 1 
(+1.3% points) compared with LDN × 4+ (−0.7% points), difference-in-difference was significant (1.9% points 
(95% CI 0.2 to 3.7, p = 0.035)).
Figure 1. Flow diagram of patient inclusion.
LDN × 1 LDN × 2–3 LDN × 4+
N (%) 3590 (31.9) 2554 (22.7) 5103 (45.4)
Female (%) 2587 (72.1) 1836 (71.9) 3821 (74.9)
Age (SD) 50.6 (12.1) 50.8 (13.6) 51.7 (12.0)
Number of dispenses one year before LDN (outcome medicines) (SD) 5.3 (10.6) 5.1 (12.5) 5.1 (11.3)
Number of users one year before (outcome medicines) (%) 2 127 (59.2) 1 482 (58.0) 2 865 (56.1)
N total 11247
Table 1. Baseline data.
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Antidepressants. There were no significant differences in DDDs of antidepressants in any group. For the 
number of users of antidepressants, there was a significantly larger reduction in LDN × 4+ (−21%, relative) than 
in LDN × 1 (−2%), which also constituted a significant difference-in-difference (2.8% points, 95% CI 1.1 to 4.4, 
p = 0.001).
For LDN × 4+, there were significant reductions in DDD in tricyclic antidepressants (−8% relative), and in 
the number of users of tricyclic antidepressants (−21%) and SSRI (−6%). There was difference-in-difference in 
number of users (2.1% points, 95% CI 0.8 to 3.5, p = 0.003) of tricyclic antidepressants between LDN × 1 (−0.2% 
points) and LDN × 4 + (−2.4% points).
psychostimulants. There were no changes in the dispensing of psychostimulants following the initiation 
of LDN use.
Mood stabilizers. There was a 13% relative increase in the number of DDDs for gabapentin and pre-
gabalin in the LDN × 1 group, but no difference in cumulative sum of DDDs for lithium and lamotrigine in 
any group. There was a relative 70% increase in the number of lamotrigine users in LDN x1 and a significant 
difference-in-difference from LDN × 4+ (0.8% points (95% CI 0.4 to 1.3, p = 0.001).
For gabapentin and pregabalin, there was also a significant difference-in-difference in the number of users 
(2.4% points, 95% CI 1.0 to 3.8, p = 0.001) between. LDN × 1 (+0.6% points) and LDN × 4+ (−1.8% points).
Discussion
We have shown that starting LDN was followed by changes in the dispensing of several psychotropic medicines. 
When comparing persistent LDN users (LDN × 4+) with individuals who collected LDN only once (LDN x1), 
there were significant difference-in-differences in DDDs of antipsychotics, and in the number of users of antie-
pileptics, antipsychotics, antidepressants, tricyclic antidepressants, lamotrigine and gabapentin and pregabalin. 
In all of these groups, the reductions in number of users were larger in LDN × 4+. There was a dose-response 
relationship between reduction in number of users and increasing LDN exposure for antiepileptics, antipsychot-
ics and antidepressants.
Major strengths of this study are the number of included participants, the completeness of the data, and 
the extended observation period. The number of participants was larger than in any other study on LDN, and 
the NorPD is a reliable, comprehensive, and complete register of all dispenses of prescription medicines to all 
Norwegian residents. The observations are from a real-world setting, and should be relevant for how LDN affect 
the use of other medicines at a population level.
Medicine group (ATC code)
Dispensed 
medicines (DDD) Difference (DDD)
pBefore After Mean 95% CI
All examined medicines
LDN × 1 225.8 239.6 13.7 (6.4 to 21.1) <0.001
LDN × 2–3 223.2 236.6 13.4 (4.2 to 22.7) 0.004
LDN × 4+ 221.8 224.5 2.7 (−3.0 to 8.5) 0.355
Antiepileptics (N03A)
LDN × 1 38.5 42.9 4.4 (0.6 to 8.2) 0.025
LDN × 2–3 37.3 40.5 3.2 (−1.9 to 8.3) 0.216
LDN × 4+ 49.2 48.8 −0.4 (−3.4 to 2.6) 0.800
Antipsychotics (N05A)
LDN × 1 3.4 4.4 1.1 (0.2 to 1.9) 0.014
LDN × 2–3 3.1 4.0 0.9 (−0.1 to 1.9) 0.082
LDN × 4+ 3.3 2.9 −0.3 (−0.7 to 0.1) 0.149
Anxiolytics (N05B)
LDN × 1 26.0 27.8 1.8 (0.1 to 3.5) 0.044
LDN × 2–3 22.0 23.3 1.3 (−0.6 to 3.2) 0.173
LDN × 4+ 16.4 17.6 1.1 (0.2 to 2.1) 0.019
Hypnotics and sedatives (N05C)
LDN × 1 76.1 81.7 5.6 (2.3 to 9.0) 0.001
LDN × 2–3 71.5 80.9 9.4 (4.1 to 14.8) 0.001
LDN × 4+ 71.4 75.8 4.4 (1.2 to 7.5) 0.006
Antidepressants (N06A)
LDN × 1 78.1 79.4 1.4 (−2.8 to 5.5) 0.519
LDN × 2–3 83.5 82.4 −1.1 (−5.6 to 3.4) 0.643
LDN × 4+ 75.2 73.2 −2.0 (−5.2 to 1.2) 0.212
Psychostimulants (N06B)
LDN × 1 3.8 3.3 −0.5 (−1.6 to 0.6) 0.393
LDN × 2–3 5.8 5.4 −0.4 (−2.2 to 1.4) 0.689
LDN × 4+ 6.2 6.1 −0.1 (−1.1 to 1.0) 0.918
Table 2. Average cumulative dose of main epileptics and psychotropic medicine groups. Dispensed to 
patients one year before and after the first dispense of LDN. Three patient groups based on the number of 
LDN dispenses: LDN × 1 (N = 3590) collected LDN once, LDN × 2–3 (N = 2554) two or three times and 
LDN × 4 + (N = 5103) four or more times. LDN: Low dose naltrexone. DDD: Defined daily dose. ATC: 
Anatomical therapeutic chemical classification.
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N % N % % points 95%CI
Any examined medicine
LDN × 1 2127 (59.2) 2147 (59.8) 0.6 (−0.9 to 2.0) 0.442
LDN × 2–3 1482 (58.0) 1525 (59.7) 1.7 (0.0 to 3.4) 0.053
LDN × 4+ 2865 (56.1) 2698 (52.9) −3.3 (−4.4 to −2.1) <0.001
Antiepileptics (N03A)
LDN × 1 546 (15.2) 599 (16.7) 1.5 (0.3 to 2.7) 0.015
LDN × 2–3 360 (14.1) 410 (16.1) 2.0 (0.5 to 3.4) 0.008
LDN × 4+ 807 (15.8) 722 (14.1) −1.7 (−2.6 to −0.7) <0.001
Antipsychotics (N05A)
LDN × 1 186 (5.2) 232 (6.5) 1.3 (0.5 to 2.0) 0.001
LDN × 2–3 137 (5.4) 133 (5.2) −0.2 (−1.0 to 0.7) 0.710
LDN × 4+ 239 (4.7) 199 (3.9) −0.8 (−1.3 to −0.3) 0.002
Anxiolytics (N02B)
LDN × 1 829 (23.1) 856 (23.8) 0.8 (−0.4 to 1.9) 0.209
LDN × 2–3 522 (20.4) 533 (20.9) 0.4 (−0.9 to 1.7) 0.519
LDN × 4+ 912 (17.9) 899 (17.6) −0.3 (−1.1 to 0.6) 0.573
Hypnotics and sedatives (N05C)
LDN × 1 1143 (31.8) 1173 (32.7) 0.8 (−0.4 to 2.1) 0.176
LDN × 2–3 779 (30.5) 834 (32.7) 2.2 (0.7 to 3.6) 0.003
LDN × 4+ 1480 (29.0) 1456 (28.5) −0.5 (−1.4 to 0.4) 0.311
Antidepressants (N06A)
LDN × 1 1045 (29.1) 1039 (28.9) −0.2 (−1.5 to 1.1) 0.803
LDN × 2–3 748 (29.3) 730 (28.6) −0.7 (−2.2 to 0.8) 0.356
LDN × 4+ 1362 (26.7) 1213 (23.8) −2.9 (−3.9 to −2.0) <0.001
Psychostimulants (N06B)
LDN × 1 31 (0.9) 41 (1.1) 0.3 (0.0 to 0.6) 0.059
LDN × 2–3 31 (1.2) 31 (1.2) 0.0 (−0.4 to 0.4) 1.000
LDN × 4+ 74 (1.5) 71 (1.4) −0.1 (−0.2 to 0.1) 0.467
Table 3. Number of users of main epileptics and psychotropic medicine groups. Dispensed to patients one 
year before and after the first dispense of LDN. Three patient groups based on the number of LDN dispenses: 
LDN × 1 (N = 3590) collected LDN once, LDN × 2–3 (N = 2554) two or three times and LDN × 4 + (N = 5103) 
four or more times. LDN: Low dose naltrexone. ATC: Anatomical therapeutic chemical classification.
Figure 2. Cumulative difference in dispensed defined daily doses (DDD) of psychotropics and antiepileptics. 
The curves display difference in DDD between persistent LDN users (LDN × 4+, N = 5103) and patients that 
collected LDN only once (LDN x1, N = 3590), (LDN × 4+ minus LDN x1). Cumulative differences relative to 
Index date (Time = 0). Cumulative dose difference >0 means more dispensing to persistent LDN users than to 
LDN x1. Asymmetry of curve across index date means difference-in-difference before and after starting LDN, 
this was statistically significant for antipsychotics only. LDN: Low dose naltrexone.
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Before-after studies have some limitations. Participants are not randomly recruited or assigned to groups, 
and there is risk of both inclusion and assignment bias. The differences in sex and age were minor, but as there 
were major differences in the dispensing of medicines before starting LDN (e.g. anxiolytics) that may indicate 
differences in psychiatric morbidity between groups. We still believe the analyses are valuable since before-after 
comparisons were made both within groups and between groups. By choosing differences in DDDs and number 
of users as main outcome measures, and also analyzing for difference-in-difference between groups also increase 
the generalizability of the study. Ideally, a control group unexposed to LDN should have been included, but our 
ethics data privacy approvals did not allow this.
Quasi-experimental studies are prone to deviation to a mean, and examples were present in this study (e.g. 
antiepileptic DDD)19. However, there were also several examples that the results deviated away from the pre-LDN 
mean of the total study population.
The analyses include multiple comparisons, and the findings should, therefore be interpreted with caution. It is 
likely some significant results found were caused by chance. However, the magnitude of some of the findings and 
the presence of dose-effect relationships suggest other explanations than chance alone.
NorPD records all dispenses outside hospitals and institutions. Dispenses to hospitalized patients could 
potentially lead to bias. We believe this is negligible since most LDN was prescribed in general practice. Less than 
1% of LDN prescribers in Norway were psychiatrists10.
It is also important to remind that the NorPD contains very little clinical information. We focused on the 
dispensing of medicines, not indications for use or clinical condition. Assessment of compliance was impossible.
In a previous study, we showed that opioid use was reduced by 47% after starting LDN. This was not compen-
sated by increased use of NSAID or other non-opioid analgesics13. In this study, we find that the number of users 
of adjuvant pain medication, such as gabapentin, pregabalin and tricyclic antidepressants, was reduced in persis-
tent LDN users. This further substantiates assumptions that LDN may have therapeutic benefits in chronic pain 
conditions. However, it is possible that quitting opioids could be a part of the observed effects on psychotropic 
medicines more than actual therapeutic effects.
We did not observe any reduction in the dispensing of anxiolytics or hypnotics. On the contrary, there were 
increases in the cumulative dose for z-hypnotics for all groups. Sleep disturbances are among the most frequently 
reported adverse effects of LDN, and may contribute together with opioid withdrawal to an increased need for 
hypnotics.
Medicine group (ATC code)
Dispensed 





(N05BA + N05CD + N03AE01)
LDN × 1 60.8 62.9 2.1 (−2.2 to 6.4) 0.340
LDN × 2–3 51.2 51.6 0.4 (−5.1 to 6.0) 0.885
LDN × 4+ 40.0 43.4 3.4 (0.8 to 6.0) 0.011
Z hypnotics (N05CF)
LDN × 1 115.4 124.9 9.5 (3.6 to 15.3) 0.002
LDN × 2–3 108.6 123.9 15.3 (6.7 to 23.9) <0.001
LDN × 4+ 102.0 110.2 8.2 (4.1 to 12.2) <0.001
Tricyclic antidepressants 
(N06AA)
LDN × 1 9.4 9.5 0.1 (−0.9 to 1.1) 0.847
LDN × 2–3 9.9 10.1 0.2 (−0.9 to 1.2) 0.773
LDN × 4+ 10.8 10.0 −0.9 (−1.6 to −0.2) 0.017
SSRI (N06AB)
LDN × 1 48.1 48.0 −0.1 (−3.4 to 3.2) 0.950
LDN × 2–3 53.2 51.3 −1.9 (−5.9 to 2.1) 0.358
LDN × 4+ 43.8 43.7 −0.1 (−2.4 to 2.2) 0.962
Other antidepressants (N06AX)
LDN × 1 20.4 21.5 1.1 (−1.3 to 3.5) 0.362
LDN × 2–3 20.3 20.7 0.4 (−1.6 to 2.4) 0.680
LDN × 4+ 20.4 19.0 −1.4 (−3.5 to 0.7) 0.184
Lamotrigine (N03AX09)
LDN × 1 4.0 4.3 0.4 (−1.4 to 2.1) 0.680
LDN × 2–3 3.2 4.1 0.9 (−0.6 to 2.5) 0.225
LDN × 4+ 5.9 5.7 −0.2 (−1.2 to 0.8) 0.664
Gabapentin + Pregabalin 
(N03AX12 + N03AX16)
LDN × 1 28.8 32.4 3.6 (0.4 to 6.8) 0.026
LDN × 2–3 28.2 30.2 2.0 (−2.2 to 6.3) 0.351
LDN × 4+ 34.8 34.2 −0.6 (−3.2 to 2.1) 0.677
Lithium (N05AM)
LDN × 1 0.5 0.5 0.0 (−0.3 to 0.2) 0.910
LDN × 2–3 0.3 0.3 0.0 (0.0 to 0.0) 0.231
LDN × 4+ 0.7 0.6 −0.1 (−0.2 to 0.1) 0.337
Table 4. Average cumulative dose of medicines in ATC subgroups (secondary outcomes). Dispensed to 
patients one year before and after the first dispense of LDN. Three patient groups based on the number of 
LDN dispenses: LDN × 1 (N = 3590) collected LDN once, LDN × 2–3 (N = 2554) two or three times and 
LDN × 4 + (N = 5103) four or more times. LDN: Low dose naltrexone. DDD: Defined daily dose. ATC: 
Anatomical therapeutic chemical classification.
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One explanation to our findings is that patients experience beneficial effects that lead to reduced need for psy-
chotropic drugs. It is plausible that naltrexone could influence mental health by interfering with the endogenous 
opioids, which may have a direct role in depression via the mesolimbic system20. Indications of a relationship 
between inflammation and psychiatric conditions such as depression21 and schizophrenia22 have paved the way 
for a separate field of research: Psychoneuroimmunology. The suggested immunomodulary effects of LDN could 
have implications for psychiatry.
In conclusion, the reductions in the use of antiepileptics and psychotropics following the initiation of persis-
tent LDN use suggest that efficacy of LDN in depression and other psychiatric conditions cannot be ruled out. 
Due to the limitations of this pharmacoepidemiological study, the results should not directly lead to changes in 
clinical practice. Randomized clinical studies on LDN in psychiatry should be conducted. LDN could be an effi-
cacious, safe and affordable treatment alternative.
Data availability
Data is available from the Norwegian Prescription Database (NorPD) for researchers who after application meet 
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